Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

BIOCAD’s biosimilar of darbepoetin alfa will be available at the end of 2018

BIOCAD announced the completion of clinical trials for the first Russian-made biosimilar of darbepoetinalfa (BCD-066), which was designed to treat anemia related to chronic kidney disease or cancer.

Innovest Global launches its Biotech and Health Services division

Innovest Global launched its anticipated Biotechnology & Health Services Division with the acquisition of a twenty percent interest in StemVax Therapeutics.

Hong Kong Polytechnic University and Axis create a Joint Center for Immunotherapy

The Hong Kong Polytechnic University will join forces with Axis Therapeutics, a newly established joint venture by Athenex, Inc. and Xiangxue Pharmaceutical.

New Russian cancer treatment technology is ready for clinical trials

Scientists at the Institute of Cytology and Genetics in Novosibirsk have developed a technology for effective cancer treatment, which allows to reduce the dose of chemotherapy several-fold.

China will bring down prices for cancer drugs

china street
China's state medical insurance administration will start a new round of negotiations with pharmaceutical companies to add more cancer drugs to the insurance list.

Scientists from Novosibirsk search for new ways of cancer treatment

In the laboratory of Research Institute of Clinical and Experimental Lymphology of the Siberian Branch of the Russian Academy of Sciences, chemists and biologists are working together to create a weapon against cancer.

Russian scientists developed a combined cancer drug

Gene Surgery, a resident of SKOLKOVO, has conducted preclinical study of AntioncoRAN-M, an original cancer drug developed in Russia.

French CDMO will manufacture innovative cancer treatments for Novartis

Novartis signed an agreement with CELLforCURE to produce innovative cancer treatments known as CAR-T therapies (chimeric antigen receptor T-cells) at the bioproduction site based in Les Ulis (Essonne).

Selexis and Symphogen expand their R&D partnership

Selexis announced that under the terms of an earlier commercial license agreement, Symphogen has opened two investigational new drug applications for clinical programs utilizing Selexis Genetic Elements.

ProBioGen and Pionyr entered their second immuno-oncology collaboration

ProBioGen AG and Pionyr Immunotherapeutics announced a second service and license agreement to develop novel antibody therapeutics.

Endocyte and ITM signed a long-term global supply agreement

Endocyte and ITM Isotopen Technologien München AG (ITM) announced that ITM´s subsidiary and Endocyte have signed a long-term global supply agreement for the highly purified, no-carrier-added Lutetium-177 (177Lu) EndolucinBeta.

CRO Pivotal and APRO entered into oncology clinical trial collaboration

clinical trials
European CRO PIVOTAL and Associació per a la recerca oncològica (APRO) have announced a close collaboration in 3 different oncology clinical trials to test new treatment strategies given in an innovative way.

New cyclotron in St. Petersburg will help to develop a novel biomarker

radiopharmaceutical drug
Russia’s first new generation cyclotron (accelerator of particles) intended for manufacturing pharmaceuticals for cancer diagnosis was installed at Dr. Berezin Medical Institute (MIBS) in St. Petersburg.

Abcam developed a new analytical antibody for Merck KGaA

merck kgaa
Abcam, a global innovator in life science reagents and tools, announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA (Darmstadt, Germany).

Prestige BioPharma and Alvogen will launch Trastuzumab biosimilar in Europe

Prestige BioPharma and Alvogen announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Trastuzumab biosimilar in Central and Eastern Europe.

Kymab and Roche entered a clinical trial agreement

clinical trials
Kymab announced Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination with Kymab's lead investigational anti-ICOS antibody therapy KY1044 in Kymab's upcoming Phase I/II clinical studies.